Kevin Luebke

kevin-luebke-bio-pic
Director, Nucleic Acid/Molecular Research, Discovery Technologies

Kevin Luebke received his Ph.D. in organic chemistry from the California Institute of Technology and did postdoctoral studies in the biophysical chemistry of nucleic acids at the University of California at Berkeley, where he was supported by an American Cancer Society fellowship.

Luebke worked for two years as a senior scientist at Hewlett Packard Laboratories, contributing to the development of nucleic acid array technologies, then joined the faculty at the University of Texas Southwestern Medical Center. There, he led efforts in the areas of biomolecule array technologies, tissue engineering, and RNA structure and function.

The emphasis of Luebke’s research program at SRI is on the structure, function, and processing of RNAs associated with disease. A central goal of this research is the discovery and development of molecules that bind to specific RNA targets and modulate their function. These molecules will be useful as probes to dissect biological systems and as drug leads. The lab takes a multidisciplinary approach to this challenge, employing a wide variety of techniques that includes chemical synthesis, high-throughput screening of chemical libraries, spectroscopic and chemical characterization of RNA structure, and biochemical analysis of RNA metabolism.

Selected Publications


Read more from SRI

  • A photo of Mary Wagner

    Recognizing the life and work of Mary Wagner 

    A cherished SRI colleague and globally respected leader in education research, Mary Wagner leaves behind an extraordinary legacy of groundbreaking work supporting children and youth with disabilities and their families.

  • Testing XRGo in a robotics laboratory

    Robots in the cleanroom

    A global health leader is exploring how SRI’s robotic telemanipulation technology can enhance pharmaceutical manufacturing.

  • SRI research aims to make generative AI more trustworthy

    Researchers have developed a new framework that reduces generative AI hallucinations by up to 32%.